<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of second-trimester pregnancy termination</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of second-trimester pregnancy termination</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of second-trimester pregnancy termination</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cassing Hammond, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jody Steinauer, MD, MAS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H9928484"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Second-trimester pregnancy termination comprises approximately 10 to 15 percent of abortions performed annually worldwide [<a href="#rid1">1,2</a>]. The United States Centers for Disease Control and Prevention (CDC) reported that, in 2018, approximately 8 percent of abortions were performed between 14 to 20 weeks and 1 percent at or after 21 weeks [<a href="#rid3">3</a>].</p><p>Second-trimester abortion is associated with more morbidity and mortality and, for some patients, more social or emotional challenges than first-trimester abortion [<a href="#rid4">4</a>]. Legal, induced abortion is rarely associated with death; from 2013 to 2017, the CDC reported 20 deaths associated with abortions in the United States, and the case-fatality ratio was 0.44 [<a href="#rid3">3</a>]. Although the mortality risk increases by 38 percent for each successive gestational week after eight weeks, abortion always remains significantly safer than childbirth in the United States [<a href="#rid5">5,6</a>].</p><p>Similar to first-trimester abortion, second-trimester procedures can be performed surgically, with dilation and evacuation (D&amp;E), or with induction (medication). This topic will provide an overview of issues relating to second-trimester pregnancy termination. The procedures for second-trimester termination with induction (medication) and D&amp;E, as well as cervical preparation prior to surgical abortion, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.)</p><p></p><p class="headingAnchor" id="H602177"><span class="h1">PROCEDURE PLANNING</span></p><p class="headingAnchor" id="H449012"><span class="h2">Indications and contraindications</span><span class="headingEndMark"> — </span>Patients terminate pregnancies in the second-trimester for many reasons. Procedures are often performed in the second trimester because of a delay in diagnosis of the pregnancy or delay in obtaining an abortion. As an example, at one large United States public hospital, 58 percent of patients having second-trimester procedures were already beyond the first trimester by the time they obtained a pregnancy<strong> </strong>test [<a href="#rid7">7</a>].</p><p>For some patients, a fetal anomaly or maternal illness (eg, early onset severe preeclampsia) is not recognized or does not present until the second trimester. Midtrimester preterm premature rupture of membranes may also be an indication for pregnancy termination.</p><p>There are no contraindications to second-trimester abortion, although some patients with medical comorbidities have an increased risk of complications. However, ongoing pregnancy and delivery are also usually associated with a risk of complications in these patients. Patients with significant medical conditions should be managed by an experienced surgeon and may require consultation with an appropriate specialist (eg, cardiologist, pulmonologist).</p><p>Laws regarding abortion vary by country and by state in the United States [<a href="#rid8">8</a>]. Most states restrict abortion after fetal viability, though the definition of viability varies by state and maternal-fetal exemptions that countermand the viability statute vary by state. Clinicians offering abortion need to become familiar with local restrictions.</p><p class="headingAnchor" id="H1856540287"><span class="h2">Counseling and informed consent</span><span class="headingEndMark"> — </span>Patients planning second-trimester pregnancy termination should be counseled regarding the decision to terminate or continue the pregnancy and surgical and induction options for the procedure. Patients should be counseled about follow-up care, contraception, methods to suppress lactation, and potential complications of the procedure. This discussion should be documented on the procedure consent form and in the medical record. (See <a class="local">'Postprocedure considerations'</a> below and  <a class="medical medical_review" href="/z/d/html/114587.html" rel="external">"Counseling in abortion care"</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Counseling and informed consent'</a>.)</p><p class="headingAnchor" id="H652738"><span class="h2">Preoperative evaluation</span><span class="headingEndMark"> — </span>Determining gestational age is a critical part of providing appropriate care. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Determining gestational age'</a>.)</p><p>The preprocedure evaluation for pregnancy termination, including the role of laboratory testing for hemoglobin or hematocrit, Rh typing (and administration of <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">Rh[D] immune globulin</a> to Rh-negative individuals), and chlamydia and/or gonorrhea are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Preparation for procedure'</a>.)</p><p class="headingAnchor" id="H12652720"><span class="h1">CHOOSING DILATION AND EVACUATION VERSUS INDUCTION TERMINATION</span><span class="headingEndMark"> — </span>Second-trimester pregnancy termination can be performed by dilating the cervix and evacuating products of conception (dilation and evacuation [D&amp;E]) or by using medication to induce delivery of the fetus and placenta. D&amp;E accounts for the great majority of second-trimester abortions in the United States [<a href="#rid9">9,10</a>]. The United States Centers for Disease Control and Prevention reported that, in 2017, uterine suction curettage was used in 94 to 98 percent of abortions at 10 to 20 weeks of gestation and 92 percent at ≥21 weeks [<a href="#rid3">3</a>].</p><p>Historically, in the 1970s to 1980s, D&amp;E was preferred because it was found to result in fewer complications than the method used for induction termination at the time, hyperosmolar instillation or <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> alone [<a href="#rid11">11-16</a>]. Most of the morbidity originally associated with second-trimester induction termination derived from prolonged induction times. The introduction of induction regimens with prostaglandins and <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> antagonists has narrowed the safety gap between surgical and medical methods by shortening the interval from induction to complete abortion.</p><p>Induction termination and D&amp;E are both safe procedures throughout the second trimester; types of morbidity vary. For example, patients undergoing D&amp;E risk uterine perforation with need for surgical repair, whereas patients undergoing medical abortion confront higher rates of hemorrhage and infection. Patients with different medical histories might have reason to fear one type of complication more than another, influencing their selection of procedure.</p><p>Given the available data and other considerations, the choice depends mainly upon patient preference and the availability of a clinician with the skills and experience to provide one or both approaches. The clinician and patient should engage in shared decision-making to consider all the factors. For patients planning second-trimester pregnancy termination, we suggest D&amp;E for those who prefer a procedure with greater control over timing and less experience of the procedure. We suggest induction (medication) abortion for patients who place a high value on avoiding surgery or have a reason to prefer an intact fetus and who are willing to accept more discomfort and awareness during the procedure and a chance of additional surgical intervention.</p><p class="headingAnchor" id="H78402977"><span class="h2">Outcomes</span><span class="headingEndMark"> — </span>Both D&amp;E and induction abortion in the second trimester are safe and effective, but D&amp;E is preferred by most patients [<a href="#rid17">17</a>]. In addition, approximately 8 percent of patients who undergo induction abortion require a surgical procedure for retained placenta. (See  <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Retained placenta'</a>.)</p><p>There are few well-designed studies comparing the two approaches [<a href="#rid17">17,18</a>]. Randomized trials are difficult to conduct because patients often decline to be randomly assigned due to a strong preference for D&amp;E (eg, in one trial, 38 percent of the patients recruited declined randomization and 67 percent of these wanted D&amp;E [<a href="#rid18">18</a>]).</p><p>The only completed randomized trial found that complication rates were comparable, but induction abortion was associated with more adverse effects and a risk of subsequent D&amp;E for retained products of conception. This trial (n = 122) compared D&amp;E and induction abortion (<a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>) at 13 to 20 weeks of gestation [<a href="#rid18">18</a>]. In terms of efficacy, 10 percent of patients in the induction group underwent a subsequent procedure for retained products of conception. The rate of complications was comparable for surgical and induction procedures (12.0 versus 11.5 percent), but the type of complication varied by the type of abortion: Blood loss &gt;500 mL was more likely in the surgical group and retained placenta in the induction group. As noted, induction abortion was more likely to result in a subsequent procedure (10 percent compared with 2 percent in the surgical group). Patients in the surgical group experienced significantly lower rates of some adverse effects: unexpected overnight stay (0 versus 31 percent) and uterine bleeding heavier than menses (4 versus 37 percent); moderate to severe pain was also less common in the surgical group, but this did not reach statistical significance (23 versus 43 percent). Patients in the surgical group found the procedure more acceptable (100 versus 53 percent would choose the same procedure in the future). This trial was limited by a lack of statistical power and a low follow-up rate (60 percent).</p><p class="headingAnchor" id="H78402983"><span class="h2">Advantages and disadvantages</span></p><p class="headingAnchor" id="H78403022"><span class="h3">Dilation and evacuation</span></p><p class="bulletIndent1"><span class="glyph">●</span>Advantages of D&amp;E include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased procedure duration and predictable timing</strong> – Although patients usually undergo one to two days of cervical preparation, experienced surgeons can perform uterine evacuation in less than 30 minutes once the cervix is dilated. Induction abortion, by contrast, may take as long as 24 hours or longer.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased cost</strong> – D&amp;E usually occurs in an outpatient facility. Induction abortion often requires admission to a higher-cost labor and delivery unit [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medical conditions that required controlled timing of the procedure</strong> – The controlled timing of D&amp;E permits planned procedures for patients whose medical conditions may worsen peripartum. Patients with bleeding diatheses, cardiac, and other maternal conditions often benefit from scheduled surgical procedures rather than less-predictable induction procedures. Patients with multiple prior uterine surgeries and placenta previa can also undergo safe D&amp;E, reducing risks of uterine rupture or hemorrhage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disadvantages of D&amp;E include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of uterine perforation</strong> – Uterine perforation is a potential risk of D&amp;E and requires further surgical intervention. (See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation", section on 'Uterine perforation'</a>.)</p><p></p><p class="headingAnchor" id="H78403003"><span class="h3">Induction abortion</span></p><p class="bulletIndent1"><span class="glyph">●</span>Advantages of induction include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Desire for an intact fetus</strong> – Some patients choose labor induction to avoid fetal destruction associated with D&amp;E. This may be due to a desire to hold the fetus. It might also provide an intact fetus for morphologic evaluation, especially when congenital anomalies are present. Representative pathologic examination may be possible with either intact D&amp;E or standard D&amp;E, depending on the diagnosis in question [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disadvantages of induction include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Increased experience of the procedure</strong> – In induction abortion, the patient experiences uncomfortable effects (bleeding, cramping, nausea, vomiting) and these occur over a longer period of time during and after the procedure than with D&amp;E [<a href="#rid18">18</a>]. The patient also has a greater awareness of the process of terminating the pregnancy. Many patients find that the predictability of D&amp;E and avoiding the memory of prolonged labor make D&amp;E less emotionally burdensome than induction abortion [<a href="#rid21">21-23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unpredictability of the timing of delivery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of hemorrhage</strong> – Second-trimester induction termination is generally associated with a higher volume of blood loss than D&amp;E in most studies, although the opposite was found in the trial described above [<a href="#rid18">18,24-26</a>]. (See  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation", section on 'Hemorrhage'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Risk of retained placenta necessitating surgical removal</strong></p><p></p><p class="headingAnchor" id="H652664"><span class="h2">Procedure setting</span><span class="headingEndMark"> — </span>Second-trimester D&amp;E is typically performed in an outpatient setting, either a specialty women's health clinic, a clinician's office equipped with a procedure room, or an ambulatory surgery center.</p><p>Second-trimester induction most commonly occurs in hospitals on a labor and delivery unit or a family planning unit within the hospital. Induction procedures can be performed in outpatient settings, with the appropriate medical staff and equipment to provide ongoing administration of induction agents, analgesia and anesthesia, monitoring of patient status, delivery of the fetus and placenta (timing is often unpredictable), and, if needed, emergency surgical management (in case of a need for immediate evacuation of either fetus or placenta) or emergency transport to an inpatient facility.</p><p>Various types of outpatient settings appear to be safe for abortion procedures. In a study of 50,111 abortions from a United States private insurance database, across all types of procedures, the incidence of adverse events was comparable for procedures performed in either an ambulatory surgery center or office-based setting (any adverse event: 3.3 versus 3.3 percent; major event: 0.3 versus 0.3 percent) [<a href="#rid27">27</a>]. Also among the over 12,000 second trimester or later abortion procedures in the study, there was no difference in the incidence of adverse events associated with ambulatory surgery centers compared with office-based settings (2.6 versus 2.6 percent).</p><p>Clinics or hospitals that provide pregnancy termination must have the appropriate medical staff, equipment, and medication to perform the procedure and manage complications and to provide analgesia and anesthesia. The National Abortion Federation, a professional organization of abortion providers in the United States, Canada, Mexico, and Colombia, has issued <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fprochoice.org%2Fwp-content%2Fuploads%2F2014NAFCPGs.pdf&amp;token=xpScufR%2BLN173%2FwSYmqLfYG2UiJaSvDiZBmmnHXymjS4xrd6p7dqdJPs2Q7plNDalSpsWzViCcsgolA31fYNFA%3D%3D&amp;TOPIC_ID=14194" target="_blank">clinical policy guidelines</a> regarding medical personnel and facilities that provide pregnancy termination [<a href="#rid28">28</a>]. These stipulate that abortions should be provided by a licensed practitioner. The minimum requirements for a facility include presence on-site of a medical staff member with updated basic life support certification; an oxygen delivery system, oral airways, self-inflating respirator bags, and bronchodilators; and uterotonics and vasopressors, including <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>. In settings in which opioids or benzodiazepines are used, appropriate antagonists must be available.</p><p>It is useful for outpatient clinics to have written protocols to address emergencies, particularly indications for emergency transport to a hospital and contact information for personnel who are able to be immediately available to facilitate transport.</p><p class="headingAnchor" id="H78403351"><span class="h1">ABORTION TECHNIQUES AND PROTOCOLS</span></p><p class="headingAnchor" id="H9928507"><span class="h2">Cervical preparation for dilation and evacuation</span><span class="headingEndMark"> — </span>Cervical preparation is performed before second-trimester dilation and evacuation procedures to decrease cervical trauma and facilitate the evacuation of the uterus. These procedures are described separately. (See  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a> and  <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">"Second-trimester pregnancy termination: Dilation and evacuation"</a>.)</p><p class="headingAnchor" id="H8858980"><span class="h2">Induction abortion</span><span class="headingEndMark"> — </span>Induction or medication abortion involves the administration of medication through one of a variety of routes to induce labor and deliver the fetus. Patient preparation, protocols, complications, and outcome are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination"</a>.)</p><p class="headingAnchor" id="H12652881"><span class="h1">POSTPROCEDURE CONSIDERATIONS</span></p><p class="headingAnchor" id="H2995211518"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Many clinicians schedule a follow-up visit at two weeks. In settings where patients live a long distance from abortion facilities, it is appropriate to schedule follow-up with another clinician, to offer routine phone follow-up, or to offer patient follow-up on an as-needed basis [<a href="#rid29">29</a>].</p><p>Complications are likely to present before a routine scheduled follow-up visit. The patient should be given detailed instructions regarding signs and symptoms of complications. Patients should be advised to call their provider if they experience any of the following symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal bleeding that soaks one to two pads hourly for two consecutive hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever &gt;100.4°F</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic or abdominal pain that is severe or persistent</p><p></p><p class="headingAnchor" id="H1658036011"><span class="h2">Contraception</span><span class="headingEndMark"> — </span>Most abortion patients should be counseled about contraception. Postabortal contraception is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p class="headingAnchor" id="H1363860502"><span class="h2">Lactation suppression</span><span class="headingEndMark"> — </span>Patients may lactate following second-trimester abortion and should be counseled about comfort measures, including use of ice, compression with a tight sports bra, and avoiding breast stimulation. Use of <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a>, a dopamine agonist used for treatment of hyperprolactinemia, has also been described. In a randomized superiority trial including approximately 70 patients with pregnancy loss or termination at 18 to 26 weeks of gestation in whom survey data were available, those receiving cabergoline (1 mg once within four hours of the procedure) compared with placebo had fewer breast symptoms (28 versus 97 percent) and were bothered less by such symptoms (2.8 versus 33 percent) at four days postprocedure [<a href="#rid30">30</a>]. These differences persisted through day 14. Side effects were similar between groups, but the study was not powered to detect such differences. Cabergoline is contraindicated in patients with hypertension. Breast engorgement after pregnancy is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">"Overview of the postpartum period: Normal physiology and routine maternal care", section on 'Breast engorgement'</a>.)</p><p class="headingAnchor" id="H9928570"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H17883972"><span class="h2">Uterine anomaly</span><span class="headingEndMark"> — </span>Approximately 2 to 4 percent of patients have some type of congenital uterine anomaly, including uterine septa, bicornuate uteri, or complete duplication of both uterus and cervix [<a href="#rid31">31</a>]. Uterine anomalies increase the likelihood of failed dilation and evacuation (D&amp;E) [<a href="#rid32">32,33</a>]. Indeed, failed abortion may lead to a diagnosis of a uterine malformation [<a href="#rid34">34</a>]. Intraoperative ultrasound greatly facilitates surgical evacuation in the setting of uterine anomalies.</p><p>There is no evidence that induction abortion requires a different regimen for patients with uterine anomalies.</p><p>Uterine anomalies are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H9928586"><span class="h2">Placental abnormalities</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placenta previa and low-lying</strong> <strong>placenta</strong> – The optimal method for termination (ie, D&amp;E, medical induction) of pregnancies complicated by placenta previa and low-lying placenta is unclear. Given concern for hemorrhage, the author performs D&amp;E for all patients with placenta previa and most patients with a low-lying placenta. Medical induction is an acceptable alternative for patients with a low-lying placenta, especially those 11 to 20 mm from the internal os, who<strong> </strong>prefer to avoid surgical management.</p><p></p><p class="bulletIndent1">Placental abnormalities do not appear to preclude the use of cervical preparation with osmotic dilators prior to termination with D&amp;E. (See  <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion", section on 'Approach by gestational age'</a>.)</p><p></p><p class="bulletIndent1">Data on the safety of termination by D&amp;E versus medical induction and use of osmotic dilators in patients with placental previa are limited.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one retrospective study including 11 patients with placenta previa undergoing pregnancy termination at 12 to 20 weeks, 4 underwent D&amp;E and 7 underwent medical termination; rates of blood loss were similar between groups [<a href="#rid35">35</a>]. One patient in the medical termination group developed serious bleeding and required blood transfusion. Eight of the 11 patients had laminaria placed before the procedure, and none of these patients bled before, during, or after insertion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In two retrospective studies including 31 patients with placenta previa undergoing second-trimester pregnancy termination by D&amp;E after laminaria placement, none experienced excessive bleeding with laminaria insertion or required blood transfusion due to procedure-related hemorrhage; operative time was comparable to patients without complete previa [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1">Clinicians contemplating medical induction of second-trimester patients might also extrapolate from data for inducing term gestations complicated by low-lying placenta, especially those with a placenta 11 to 20 mm from the cervical os. In a meta-analysis including 10 cohort studies (approximately 600 patients) of vaginal births in patients with low-lying placenta (defined as a distance of 0 to 10 and 11 to 20 mm from the internal os) versus without (ie, &gt;20 mm from the internal os), patients with placentas ≤10 mm compared with 11 to 20 mm and &gt;20 mm from the cervical os had a higher risk of emergency cesarean birth due to intrapartum hemorrhage (45, 14, and 10 percent, respectively) [<a href="#rid38">38</a>]. Rates of postpartum hemorrhage were similar between groups. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6809.html" rel="external">"Placenta previa: Management", section on 'Delivery of patients with a low-lying placenta'</a>.)</p><p></p><p class="bulletIndent1">Uterine artery embolization (UAE) or feticide prior to second-trimester pregnancy termination may help reduce blood loss, but the data are even more limited [<a href="#rid39">39-41</a>]. Until additional information is available regarding the safety and efficacy of these methods prior to termination, use should be considered on an individualized basis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placenta accreta spectrum (PAS)</strong> – Suspected PAS is often managed with gravid hysterectomy (ie, hysterectomy with the fetus remaining in situ) or a "double set-up" D&amp;E (in which the patient and operating room are prepped for emergency hysterectomy, if needed), depending on the degree of concern for placental invasion and the patient's future reproductive plans. These procedures should be performed in hospitals capable of managing life-threatening hemorrhage.</p><p></p><p class="bulletIndent1">Small series have described management with UAE (prophylactic or postprocedure), fetal extraction via hysterotomy, medical induction, or D&amp;E [<a href="#rid42">42-44</a>]. In a few cases, the placenta was removed, but in most cases, it was left in situ, with hysteroscopic resection performed under ultrasound or laparoscopic guidance at a later date when the placenta was nonfunctional (normal human chorionic gonadotropin level and reduced blood flow on Doppler at the placental interface). Representative studies include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one retrospective study including 29 patients with PAS undergoing second-trimester termination, 7 patients underwent prophylactic UAE followed by hysterotomy (placenta was removed), and the remainder underwent medical induction followed by adjuvant treatment for the remaining placenta (eg, UAE, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a>, D&amp;C) [<a href="#rid43">43</a>]. All three patients (10 percent) requiring hysterectomy were in the hysterotomy group. Although this study utilized adjuvant methotrexate, there is no convincing evidence that methotrexate improves outcomes in these patients, and there is risk for potential harm (eg, methotrexate-related toxicity) [<a href="#rid45">45</a>]; thus, we strongly caution against methotrexate use in this setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another retrospective study including seven patients with PAS undergoing postprocedure UAE for management of hemorrhage after second-trimester D&amp;E, three patients (43 percent) were treated successfully and four (57 percent) required hysterectomy (in one patient, a prophylactic, rather than postprocedure, UAE was performed) [<a href="#rid44">44</a>]; placentas were removed at the time of D&amp;E in all patients.</p><p></p><p class="bulletIndent1">The diagnosis and management of PAS disorders are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6759.html" rel="external">"Placenta accreta spectrum: Clinical features, diagnosis, and potential consequences"</a> and  <a class="medical medical_review" href="/z/d/html/83129.html" rel="external">"Placenta accreta spectrum: Management"</a>.)</p><p></p><p class="headingAnchor" id="H9928593"><span class="h2">Prior uterine scar</span><span class="headingEndMark"> — </span>A uterine scar from a prior cesarean birth or myomectomy is not a contraindication to induction abortion, but many clinicians prefer D&amp;E for these patients. Uterine rupture is a risk of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> use at any time during pregnancy. The risk is higher in patients with increasing gestational age and multiple cesarean births [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination", section on 'Uterine rupture'</a> and  <a class="medical medical_review" href="/z/d/html/5434.html" rel="external">"Misoprostol as a single agent for medical termination of pregnancy", section on 'Patients with a uterine scar'</a>.)</p><p>It is uncertain whether a surgical approach entirely eliminates the risk of uterine rupture. During the process for a D&amp;E, the uterus contracts in response to the insertion of osmotic dilators and the surgery itself, and with use of <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> or other agents as pharmacologic ripening agents or uterotonics. Theoretically, some events that are classified as a uterine perforation at the time of D&amp;E on a scarred uterus may represent an occult uterine rupture.</p><p class="headingAnchor" id="H448925"><span class="h2">Multifetal gestation</span><span class="headingEndMark"> — </span>Multifetal gestation is managed in the same way as a singleton pregnancy for second-trimester abortion. There is no evidence that a modification is required of the surgical technique or medication regimen, though patients might confront a higher risk of uterine atony and hemorrhage due to greater uterine size. Operators should manage uterine atony as they do at similar gestational size. </p><p class="headingAnchor" id="H5769583"><span class="h2">Fetal anomaly or fetal demise</span><span class="headingEndMark"> — </span>Second-trimester abortion is often performed for the indication of a fetal anomaly. Diagnosis of fetal anomalies and counseling for patients undergoing termination for a fetal anomaly are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a> and  <a class="medical medical_review" href="/z/d/html/14193.html" rel="external">"Pregnancy termination and potential psychiatric outcomes", section on 'Termination for fetal anomalies'</a>.)</p><p>For fetal demise, management of uterine evacuation is generally the same as induced abortion and morbidity is similar, except that risk of transfusion may be higher with intrauterine fetal demise [<a href="#rid47">47</a>] Management of fetal demise is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6740.html" rel="external">"Stillbirth: Maternal care"</a>.)</p><p class="headingAnchor" id="H9928600"><span class="h2">Chorioamnionitis</span><span class="headingEndMark"> — </span>Midtrimester chorioamnionitis may develop in the presence of preterm premature rupture of membranes. This may occur spontaneously and, in some cases, midtrimester rupture of membranes is the indication for pregnancy termination. Alternatively, it may develop after insertion of osmotic dilators or during a prolonged induction procedure. (See  <a class="medical medical_review" href="/z/d/html/6741.html" rel="external">"Prelabor rupture of membranes before and at the limit of viability", section on 'Chorioamnionitis'</a>.)</p><p>Patients with chorioamnionitis present with fever and other possible findings (pelvic and abdominal pain, uterine contractions, purulent cervical discharge). Uterine evacuation is the cornerstone of treating second-trimester chorioamnionitis. No studies have evaluated the relative benefits of surgical versus medical abortion in this setting.</p><p>For patients who are hemodynamically stable and have early chorioamnionitis, surgical or induction abortion may proceed in the same manner as for other patients. In our practice, if a patient develops a persistent temperature elevation &gt;100.4°F, we treat with antibiotics, in the same manner as chorioamnionitis during labor. (See  <a class="medical medical_review" href="/z/d/html/6762.html" rel="external">"Clinical chorioamnionitis", section on 'Antibiotic therapy'</a>.)</p><p>Given high mortality rates associated with septic abortion, evacuation should be expedited for patients who are overtly septic. The best option for the patient must be individualized, and the surgeon should choose the one that best expedites uterine evacuation. Approaches include:</p><p class="bulletIndent1"><span class="glyph">●</span>Place osmotic dilators to prepare for D&amp;E. There is no evidence that use of osmotic dilators exacerbates infection in patients with chorioamnionitis. Some patients with overt sepsis have already begun laboring and might require less cervical preparation than uninfected patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiate an effective induction protocol. Osmotic dilators may be placed or <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> administered concurrent with initiation of uterotonics to begin the induction to allow the flexibility to convert to D&amp;E if induction becomes prolonged. Unfortunately, placement of osmotic dilators may prolong induction abortion intervals in some cases [<a href="#rid48">48-50</a>].</p><p></p><p class="headingAnchor" id="H582424712"><span class="h2">Failed induction</span><span class="headingEndMark"> — </span>Despite use of an appropriate induction regimen, some patients initially fail to abort. It is appropriate, in such cases, to either treat the patient with another cycle of <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> or to divert to D&amp;E abortion. Hysterotomy abortion is rarely necessary [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3267093480"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p class="headingAnchor" id="H18245901"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15750.html" rel="external">"Patient education: Abortion (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/8400.html" rel="external">"Patient education: Abortion (pregnancy termination) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H9928622"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scope</strong> – Second-trimester (14 to &lt;28 weeks of gestation) pregnancy termination comprises 10 to 15 percent of the approximately 42 million abortions performed annually worldwide. It can be performed as a surgical evacuation of the uterus (dilation and evacuation [D&amp;E]) or by using medication to induce delivery of the fetus and placenta. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications</strong> – Indications for second-trimester abortion include socioeconomic and psychosocial factors (often in cases of a delay in diagnosis of the pregnancy or delay in obtaining an abortion), fetal anomaly, preterm premature rupture of membranes, or maternal illness. There are no contraindications to second-trimester abortion, although some patients with medical comorbidities have an increased risk of complications. (See <a class="local">'Indications and contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preprocedure planning</strong> – Preprocedural counseling, determination of gestational age, and the role of laboratory testing (for hemoglobin or hematocrit, Rh typing [and administration of Rh(D) <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> to Rh-negative individuals], and chlamydia and/or gonorrhea) are described in detail separately. (See <a class="local">'Counseling and informed consent'</a> above and <a class="local">'Preoperative evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Determining gestational age'</a> and  <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Preparation for procedure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of procedure</strong> – Both D&amp;E and induction methods are safe and effective options for second-trimester pregnancy termination. The choice depends mainly on patient preference and the availability of a clinician with the skills and experience to provide one or both approaches. For patients planning second-trimester pregnancy termination (see <a class="local">'Choosing dilation and evacuation versus induction termination'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>D&amp;E</strong> – We suggest D&amp;E for those who prefer a procedure with greater control over timing and less experience of the procedure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medication abortion</strong> – We suggest induction (medication) abortion for patients who place a high value on avoiding surgery or have a reason to prefer an intact fetus and who are willing to accept more discomfort and awareness during the procedure, a larger blood loss, and a chance of additional surgical intervention (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – The patient should be given detailed instructions regarding signs and symptoms of complications, including fever, excessive vaginal bleeding, or severe or persistent pelvic or abdominal pain. Many clinicians schedule a follow-up visit at two weeks after second-trimester pregnancy termination. Options for contraceptives, as well as a discussion regarding lactation suppression, are typically part of counseling before and after the procedure. (See <a class="local">'Postprocedure considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk pregnancies</strong> – Patients with higher-risk pregnancies (eg, uterine and placental abnormalities, prior uterine scar) can be managed with second-trimester abortion, but the approach may vary. (See <a class="local">'Special circumstances'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 135: Second-trimester abortion. Obstet Gynecol 2013; 121:1394. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Sedgh G, Henshaw S, Singh S, et al. Induced abortion: estimated rates and trends worldwide. Lancet 2007; 370:1338.</a></li><li><a class="nounderline abstract_t">Kortsmit K, Jatlaoui TC, Mandel MG, et al. Abortion Surveillance - United States, 2018. MMWR Surveill Summ 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003; 35:16.</a></li><li><a class="nounderline abstract_t">Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 2004; 103:729.</a></li><li><a class="nounderline abstract_t">Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol 2012; 119:215.</a></li><li><a class="nounderline abstract_t">Drey EA, Foster DG, Jackson RA, et al. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynecol 2006; 107:128.</a></li><li class="breakAll">http://www.guttmacher.org/sections/abortion.php (Accessed on November 17, 2015).</li><li><a class="nounderline abstract_t">Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004; 104:174.</a></li><li><a class="nounderline abstract_t">Grimes DA, Schulz KF, Cates WJ Jr. Prevention of uterine perforation during curettage abortion. JAMA 1984; 251:2108.</a></li><li><a class="nounderline abstract_t">Kafrissen ME, Schulz KF, Grimes DA, Cates W Jr. Midtrimester abortion. Intra-amniotic instillation of hyperosmolar urea and prostaglandin F2 alpha v dilatation and evacuation. JAMA 1984; 251:916.</a></li><li><a class="nounderline abstract_t">Grimes DA, Schulz KF, Cates W Jr, Tyler CW Jr. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. N Engl J Med 1977; 296:1141.</a></li><li><a class="nounderline abstract_t">Hern WM. Serial multiple laminaria and adjunctive urea in late outpatient dilatation and evacuation abortion. Obstet Gynecol 1984; 63:543.</a></li><li><a class="nounderline abstract_t">Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol 1983; 62:185.</a></li><li><a class="nounderline abstract_t">Strauss LT, Gamble SB, Parker WY, et al. Abortion surveillance--United States, 2004. MMWR Surveill Summ 2007; 56:1.</a></li><li class="breakAll">Tietze C, Henshaw SK. Induced abortion: a world review, 3rd ed, Alan Guttmacher Institute, New York 1986.</li><li><a class="nounderline abstract_t">Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial. BJOG 2004; 111:148.</a></li><li><a class="nounderline abstract_t">Kelly T, Suddes J, Howel D, et al. Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial. BJOG 2010; 117:1512.</a></li><li><a class="nounderline abstract_t">Cowett AA, Golub RM, Grobman WA. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol 2006; 194:768.</a></li><li><a class="nounderline abstract_t">Gawron LM, Hammond C, Ernst LM. Perinatal pathologic examination of nonintact, second-trimester fetal demise specimens: the value of standardization. Arch Pathol Lab Med 2013; 137:1083.</a></li><li><a class="nounderline abstract_t">Freeman EW. Abortion: subjective attitudes and feelings. Fam Plann Perspect 1978; 10:150.</a></li><li><a class="nounderline abstract_t">Rooks JB, Cates W Jr. Abortion methods: morbidity, costs and emotional impact. 3. Emotional impact of D&amp;E vs. instillation. Fam Plann Perspect 1977; 9:276.</a></li><li><a class="nounderline abstract_t">Kaltreider NB, Goldsmith S, Margolis AJ. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol 1979; 135:235.</a></li><li><a class="nounderline abstract_t">Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131. Contraception 2013; 87:331.</a></li><li><a class="nounderline abstract_t">Niinimäki M, Suhonen S, Mentula M, et al. Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. BMJ 2011; 342:d2111.</a></li><li><a class="nounderline abstract_t">Thonneau P, Poirel H, Fougeyrollas B, et al. A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Hum Reprod 1995; 10:1512.</a></li><li><a class="nounderline abstract_t">Roberts SCM, Upadhyay UD, Liu G, et al. Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions. JAMA 2018; 319:2497.</a></li><li class="breakAll">2013 Clinical Policy Guidelines. National Abortion Federation. Available at: https://www.prochoice.org/wp-content/uploads/2013NAFCPGsforweb.pdf (Accessed on June 03, 2013).</li><li class="breakAll">Espey E, MacIsaac L. Management of unintended and abnormal pregnancy: Comprehensive abortion care, Paul M, Lichtenberg S, Borgatta L, et al (Eds), Wiley-Blackwell, Oxford, London 2003. p.211.</li><li><a class="nounderline abstract_t">Henkel S, Johnson SA, Reeves MF, et al. Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss A  Randomized Controlled Trial. Obstet Gynecol 2023; 141:1115.</a></li><li><a class="nounderline abstract_t">Jurkovic D, Gruboeck K, Tailor A, Nicolaides KH. Ultrasound screening for congenital uterine anomalies. Br J Obstet Gynaecol 1997; 104:1320.</a></li><li><a class="nounderline abstract_t">Pennes DR, Bowerman RA, Silver TM, Smith SJ. Failed first trimester pregnancy termination: uterine anomaly as etiologic factor. J Clin Ultrasound 1987; 15:165.</a></li><li><a class="nounderline abstract_t">Gürkan Zorlu C, Aral K, Ekici E, et al. Causative factors in first trimester abortion failure. Adv Contracept 1996; 12:63.</a></li><li><a class="nounderline abstract_t">Valle RF, Sabbagha RE. Management of first trimester pregnancy termination failures. Obstet Gynecol 1980; 55:625.</a></li><li><a class="nounderline abstract_t">Nakayama D, Masuzaki H, Miura K, et al. Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost. Contraception 2007; 75:238.</a></li><li><a class="nounderline abstract_t">Halperin R, Vaknin Z, Langer R, et al. Late midtrimester pregnancy termination in the presence of placenta previa. J Reprod Med 2003; 48:175.</a></li><li><a class="nounderline abstract_t">Thomas AG, Alvarez M, Friedman F Jr, et al. The effect of placenta previa on blood loss in second-trimester pregnancy termination. Obstet Gynecol 1994; 84:58.</a></li><li><a class="nounderline abstract_t">Jansen C, de Mooij YM, Blomaard CM, et al. Vaginal delivery in women with a low-lying placenta: a systematic review and meta-analysis. BJOG 2019; 126:1118.</a></li><li><a class="nounderline abstract_t">Ruano R, Dumez Y, Cabrol D, Dommergues M. Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa--does feticide decrease postdelivery maternal hemorrhage? Fetal Diagn Ther 2004; 19:475.</a></li><li><a class="nounderline abstract_t">Pei R, Wang G, Wang H, et al. Efficacy and Safety of Prophylactic Uterine Artery Embolization in Pregnancy Termination with Placenta Previa. Cardiovasc Intervent Radiol 2017; 40:375.</a></li><li><a class="nounderline abstract_t">Wang N, Li XM, Fei YL, et al. Effects of prophylactic uterine artery embolization on second-trimester induced abortions in patients with placenta previa. Int J Gynaecol Obstet 2018; 143:205.</a></li><li><a class="nounderline abstract_t">Ou J, Peng P, Teng L, et al. Management of patients with placenta accreta spectrum disorders who underwent pregnancy terminations in the second trimester: A retrospective study. Eur J Obstet Gynecol Reprod Biol 2019; 242:109.</a></li><li><a class="nounderline abstract_t">Cui R, Li M, Lu J, et al. Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: a retrospective study. BMC Pregnancy Childbirth 2018; 18:298.</a></li><li><a class="nounderline abstract_t">Steinauer JE, Diedrich JT, Wilson MW, et al. Uterine artery embolization in postabortion hemorrhage. Obstet Gynecol 2008; 111:881.</a></li><li><a class="nounderline abstract_t">Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol 2019; 220:511.</a></li><li><a class="nounderline abstract_t">Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:1117.</a></li><li><a class="nounderline abstract_t">Edlow AG, Hou MY, Maurer R, et al. Uterine evacuation for second-trimester fetal death and maternal morbidity. Obstet Gynecol 2011; 117:307.</a></li><li><a class="nounderline abstract_t">Borgatta L, Chen AY, Vragovic O, et al. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 2005; 72:358.</a></li><li><a class="nounderline abstract_t">Jain JK, Mishell DR Jr. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 1996; 175:173.</a></li><li><a class="nounderline abstract_t">Thong KJ, Baird DT. A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy. Contraception 1992; 46:11.</a></li></ol></div><div id="topicVersionRevision">Topic 14194 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812485" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACOG Practice Bulletin No. 135: Second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17933648" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Induced abortion: estimated rates and trends worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237897" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Abortion Surveillance - United States, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12602753" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The accessibility of abortion services in the United States, 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051566" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors for legal induced abortion-related mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22270271" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The comparative safety of legal induced abortion and childbirth in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394050" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors associated with presenting for abortion in the second trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394050" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors associated with presenting for abortion in the second trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229018" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Methods for induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6708260" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevention of uterine perforation during curettage abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6582285" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Midtrimester abortion. Intra-amniotic instillation of hyperosmolar urea and prostaglandin F2 alpha v dilatation and evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857158" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700903" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serial multiple laminaria and adjunctive urea in late outpatient dilatation and evacuation abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866362" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18030283" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abortion surveillance--United States, 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18030283" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abortion surveillance--United States, 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723752" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20860598" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522411" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899064" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perinatal pathologic examination of nonintact, second-trimester fetal demise specimens: the value of standardization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/658319" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Abortion: subjective attitudes and feelings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/923758" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Abortion methods: morbidity, costs and emotional impact. 3. Emotional impact of D&amp;E vs. instillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474678" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The impact of midtrimester abortion techniques on patients and staff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218863" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508042" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593526" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946727" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946727" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946727" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss A  Randomized Controlled Trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386036" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ultrasound screening for congenital uterine anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3134410" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Failed first trimester pregnancy termination: uterine anomaly as etiologic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739517" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Causative factors in first trimester abortion failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6445048" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Management of first trimester pregnancy termination failures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303496" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12698775" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Late midtrimester pregnancy termination in the presence of placenta previa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8008324" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The effect of placenta previa on blood loss in second-trimester pregnancy termination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30663270" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Vaginal delivery in women with a low-lying placenta: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539869" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Second- and third-trimester therapeutic terminations of pregnancy in cases with complete placenta previa--does feticide decrease postdelivery maternal hemorrhage?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27853824" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and Safety of Prophylactic Uterine Artery Embolization in Pregnancy Termination with Placenta Previa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076600" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of prophylactic uterine artery embolization on second-trimester induced abortions in patients with placenta previa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31580962" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of patients with placenta accreta spectrum disorders who underwent pregnancy terminations in the second trimester: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29996794" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management strategies for patients with placenta accreta spectrum disorders who underwent pregnancy termination in the second trimester: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378747" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Uterine artery embolization in postabortion hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30849356" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384128" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21252744" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Uterine evacuation for second-trimester fetal death and maternal morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16246662" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694046" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424619" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
